

## **Life Technologies Partners with German Cancer Research Center to Create World-Class Genome Sequencing Facility**

**CARLSBAD, Calif. and HEIDELBERG, Germany – June 2, 2010 – Life Technologies Corporation (NASDAQ: LIFE) and the German Cancer Research Center (Deutsches Krebsforschungszentrum or DKFZ), today announced their collaboration to create the National High-Throughput Sequencing Center. This exclusive partnership will create the largest sequencing facility in Germany and the first national sequencing center in Europe dedicated to systems biology.**

The center will operate 10 SOLiD™ 4 *hq* systems and will initially sequence 1000 whole human cancer genomes for Germany's national contribution to the International Cancer Genome Consortium (ICGC). The facility will be partially funded by the German Federal Ministry of Education and Research.

Systems biology is the study of an organism as an integrated and interacting network of genes, proteins and biochemical reactions that give rise to life. Often, experiments in systems biology require precise measurements of cellular events over time and assess changes in DNA sequence, RNA transcription or genomic copy number. Therefore, these experiments require substantially more sequencing throughput than experiments that are not examining such dynamic changes in cellular events.

“Our aim is to understand the dynamic complexity of cellular processes on both the DNA and RNA level and how slight perturbations of those pathways contribute to the development of diseases like cancer,” said Professor Roland Eils from DFKZ. “Therefore, it is of the utmost importance to be able to obtain quantitative precise measurements. We are confident that this collaboration with Life Technologies will help us generate the highest quality data possible using the SOLiD™ technology.”

The SOLiD™ System is used globally in experiments to better understand the genetic nature of diseases such as cancer, diabetes, neurological disorders and other diseases. Its throughput, accuracy and flexibility allow researchers to generate the data they need for their experiments.

“Life Technologies is proud to be the technology partner of choice for this new and exciting sequencing center and to be working with DFKZ, a renowned institution in Germany in life science research devoted to studying the complexities of cancer,” said Mark Stevenson, President and Chief Operating Officer for Life Technologies. “This center will be the first facility that will systematically bring high-throughput sequencing technologically into systems biology applications on a large scale.”

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is the largest biomedical research institute in Germany and is a member of the Helmholtz Association of National Research Centers. More than 2,000 staff members, including 850 scientists, are investigating the mechanisms of cancer and are working to identify cancer risk factors. They provide the foundations for developing novel approaches in the prevention, diagnosis, and treatment of cancer. In addition, the staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. The Center

is funded by the German Federal Ministry of Education and Research (90%) and the State of Baden-Württemberg (10%).

Dr. Stefanie Seltmann  
Leiterin Presse- und Öffentlichkeitsarbeit  
Deutsches Krebsforschungszentrum  
Im Neuenheimer Feld 280  
D-69120 Heidelberg  
T: +49 6221 42 2854  
F: +49 6221 42 2968  
[presse@dkfz.de](mailto:presse@dkfz.de)